ReviewFrontiers in bioengineering and biotechnology2026
Stent biomechanics in hemodialysis-related left brachiocephalic vein stenosis: from site-specific loading to a staged device-validation framework.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemodialysis-related left brachiocephalic vein stenosis is usually managed as one local variant of central venous stenosis, yet its mechanical environment is distinctive. The vein follows a long, multi-axially curved retrosternal course through a narrow window between the manubrium and the aortic arch, bounded by two separate junctions, the lateral venous angle and the medial brachiocephalic-caval confluence. An implanted stent is therefore exposed to focal unidirectional compression, cyclic bending and torsion, short landing zones, and branch-coverage risk, conditions not reproduced by circumferential radial testing. The sternum-aortic corridor reported in affected patients, about 4.6 mm, is narrower than the nominal diameter of stents deployed there, placing the implied compression at or beyond the lowest level characterized in published bench comparisons; pulsatile durability testing covers only cardiac-frequency diametric cycling, and pooled cohorts seldom report the segment separately. This Review synthesizes published anatomical, clinical, engineering, and computational evidence and reframes the problem as a site-specific biomechanical and device-validation question with three validation priority stages (P1-P3). P1 (required) evaluates base-platform mechanics, structure, fatigue, and deployment: focal crush resistance and recovery, radial resistive versus chronic outward force, bending and torsion durability, foreshortening, deployment accuracy, branch preservation and, for covered constructs, covering fatigue. P2 (required) evaluates anatomy-specific hemodynamics of the same platform by patient-specific computational modeling and experimental flow testing, reporting shear, residence, gradient, edge-recirculation, branch-flow, and pressure-loss metrics against matched comparators. P3 (optional) covers an added drug, coating, or surface; baseline thrombogenicity, hemocompatibility, tissue compatibility, and structural integrity remain required base-platform attributes. We state two falsifiable hypotheses with the bench, computational, imaging, and clinical evidence that would support or refute them: H1 (mechanical), that resistance to focal unidirectional crush may govern stent deformation, durability, and in-stent restenosis localization more strongly than circumferential radial resistive force alone; and H2 (hemodynamic), that stent architecture and edge configuration may generate spatially reproducible disturbed-flow regions adding incremental prediction of later in-stent restenosis distribution beyond anatomical and procedural covariates. Direct prospective evidence remains sparse: the framework is a problem definition and validation roadmap, not a clinical algorithm, device ranking, or evidence of superior performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.